PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma

: Novel therapies are needed for patients with hepatoblastoma due to an increasing incidence of disease and poor prognosis for advanced, refractory, and recurrent disease. PIM kinases promote tumorigenesis in hepatoblastoma. A novel PIM inhibitor, PIM447, has shown promise in inhibiting oncogenesis in hematologic and lymphoid malignancies. We hypothesized that PIM inhibition with PIM447 would result in decreased tumorigenesis in hepatoblastoma.

Source: Journal of Pediatric Surgery - February 23, 2021 Category: Surgery Authors: Nikita Wadhwani, Hooper R. Markert, Raoud Marayati, Laura V Bownes, Colin H. Quinn, Jamie M. Aye, Jerry E. Stewart, Karina J. Yoon, Elizabeth A. Beierle Source Type: research